ICPT Jan 2024 35.000 call
| Previous close | 2.5000 |
| Open | 2.5000 |
| Bid | 2.1500 |
| Ask | 3.4000 |
| Strike | 35.00 |
| Expiry date | 2024-01-19 |
| Day's range | 2.5000 - 2.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 694 |
- Zacks
Intercept (ICPT) Stock Gains 13% in 3 Months: Here's Why
Intercept (ICPT) gains 13% in the past three months on positive regulatory and pipeline updates.
- GlobeNewswire
Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning
Outstanding debt reduced by 54% or $388.9 million and annual cash interest expense reduced by 58% or $13.6 million Company well-positioned to drive continued growth in PBC, progress NASH program, expand and advance pipeline MORRISTOWN, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced a summary of t
- GlobeNewswire
Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology
Combined clinical trial and real-world data with six years of follow-up provides important evidence of efficacy Analysis compares findings from the Phase 3 POISE trial and open-label extension to natural history data from the Global PBC and UK-PBC patient registries MORRISTOWN, N.J., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral li
